Bixiye
QP103-20 Commercial Pharmacy Benefit Exclusion for Emtricitabine-Tenofovir Disoproxil Fumarate Tablet 200-300 mg
Taariikhda uu dhaqangalayo barnaamijka: Okt 28, 2020
Natiijooyinka Raadinta
Soo bandhiga 2331 - 2340 ee natiijooyinka 3701
Bixiye
QP104-20 Update: Cotiviti to Perform Focused and Limited Hospital Bill Validation (HBV) Services
Taariikhda uu dhaqangalayo barnaamijka: Okt 28, 2020
Bixiye
QP99-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Insulin Pump PA with QL
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
P79-20 Change in Medical Necessity Criteria to InterQual® for Substance Use Disorder Admissions
Taariikhda uu dhaqangalayo Barnaamijka: Nov 02, 2020
Bixiye
P83-20 eviCore Healthcare Specialty Utilization Management (UM) Program - Laboratory Management Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers
Taariikhda uu dhaqangalayo Barnaamijka: Nov 02, 2020
Bixiye
P77-20 2021 Medicare Product Acupuncture Benefit Changes
Taariikhda uu dhaqangalayo Barnaamijka: Nov 02, 2020
Bixiye
P76-20 2021 Renewal Changes Summary for Institutional Providers
Taariikhda uu dhaqangalayo barnaamijka: Okt 01, 2020
Bixiye
2020 October Bulletins
Taariikhda uu dhaqangalayo barnaamijka: Okt 01, 2020
Bixiye
P15R1-20 Update: Change in Requirements for Newborn Precertification Process for Minnesota Health Care Programs
Taariikhda uu dhaqangalayo barnaamijka: Okt 01, 2020
Bixiye
QP102-20 Introducing eviCore’s new intelliPath® Technology
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020